

Supplementary materials

- Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncol*. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14. PMID: 34000246.
- Tewari KS, Monk BJ, Vergote I, et al. VP4_2021 - EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract VP4-2021
- FDA accepts Libtayo® (cemiplimab-rwlc) for priority review for advanced cervical cancer. News release. Regeneron. September 28, 2021. Accessed September 28, 2021. <https://bit.ly/39GMyLK>
- Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. *Lancet*. 2019;393(10167):169-182.
- Jin J. HPV Infection and Cancer. *JAMA*. 2018;319(10):1058.
- Bandini M, Ross JS, Zhu Y, et al. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. *Eur Urol Oncol*. 2020;S2588-9311(20)30176-0.
- Borella F, Preti M, Bertero L, et al. Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. *Int J Mol Sci*. 2020;22(1):190.
- Buonerba C, Pagliuca M, Vitrone FM, et al. Immunotherapy for penile cancer. *Future Sci OA*. 2017;3(3):FSO195.
- Skeate JG, Woodham AW, Einstein MH, et al. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases, *Human Vaccines & Immunotherapeutics* 2016; 12:6, 1418-1429.
- Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. *Invest New Drugs*. 2021. doi: 10.1007/s10637-021-01100-x. Epub ahead of print. PMID: 33770291.
- Lee k, Park J, Oh D, et al. Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors. Presented at: 2021 ESMO Congress; September 16-21, 2021; Abstract 977P
- Pouessel D, Beylot-Barry M, Esma SM, et al. Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program. Presented at: 2021 ESMO Congress; September 16-21, 2021; Abstract 715P
- Frommer RS, Mileschkin L, Manzyuk L, et al. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study. Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women's Cancer; March 19-21, 2021; Virtual. Abstract 11603.
- How JA, Jazaeri AA, Soliman PT, et al. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. *Sci Rep* 2021; 11: 3667.
- Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. *N Engl J Med* 2021;385:1856-67.